4//SEC Filing
Crystal Adam 4
Accession 0001209191-22-001700
CIK 0001662579other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 4:30 PM ET
Size
11.0 KB
Accession
0001209191-22-001700
Insider Transaction Report
Form 4
Crystal Adam
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2022-01-04$6.49/sh+15,000$97,350→ 30,000 total - Sale
Common Stock
2022-01-04$31.59/sh−13,946$440,547→ 16,054 total - Sale
Common Stock
2022-01-04$32.66/sh−1,054$34,420→ 15,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-01-04−15,000→ 112,292 totalExercise: $6.49Exp: 2029-04-08→ Common Stock (15,000 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.32 to $33.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.
Documents
Issuer
C4 Therapeutics, Inc.
CIK 0001662579
Entity typeother
Related Parties
1- filerCIK 0001825445
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 4:30 PM ET
- Size
- 11.0 KB